Single DermaVir Immunization in HIV-1 Infected Patients on HAART
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
- DermaVir is a plasmid DNA-containing synthetic nanomedicine. It is administered
topically with DermaPrep to target Langerhans cells. Langerhans cells with DermaVir
migrate to lymph nodes and express HIV-like particles that induce immune responses to
kill HIV-infected cells.
- Hypothesis: Single DermaVir immunization is safe and immunogenic measured by induction
of HIV-specific precursor/memory T cell responses.
- GIHU004 was a phase I dose escalation study conducted in Hungary. It evaluated the
safety and immunogenicity of three dosing regimens of topical DermaVir immunization for
the treatment of HIV-infected individuals on fully suppressive highly active
antiretroviral therapy (HAART).